The Bear and Bull Cases for Amarin
Oct 16th 2013 7:21PM
Updated Oct 16th 2013 7:22PM
This episode of The Motley Fool's Market Checkup dives into the hottest headlines, looks at the biggest market movers in the health-care sector, and also discusses the implementation of the Affordable Care Act, also known as Obamacare.
This segment from the show focuses on Amarin and its triglyceride-lowering drug Vascepa. Today, trading of Amarin's shares was halted as a highly anticipated FDA advisory committee meeting convened to discuss the proposed label expansion for Vascepa.
Investors may recall that shares of Amarin plunged 20% after the committee's briefing documents were released last week, but shares could fall further tomorrow, as the advisory committee voted 9-2 against approving Vascepa.
It's difficult to tell how the market will react to the bad news, and management is set to discuss the decision at a conference call this evening. However, in this video, analysts David Williamson and Max Macaluso look at the bear and bull theses for this stock.
Incredible growth stock to get on your radar
This incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!
Note: This video was recorded before the results from Amarin's FDA panel released its decision.
The article The Bear and Bull Cases for Amarin originally appeared on Fool.com.Alison Southwick and Max Macaluso, Ph.D., own shares of Apple. David Williamson owns shares of Amarin. The Motley Fool recommends and owns shares of Amazon.com, Apple, and Google. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.